Table 2 Some FDA-approved nanocarriers for the treatment of ocular diseases
From: Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
Product | Nanocarriers | Drug | Indications | Approval date |
|---|---|---|---|---|
Visudyne® | Liposome | Verteporfin | Wet age macular degeneration | 2000 |
Durezol® | Nanoemulsion | Difluprednate | Postoperative ocular inflammation | 2002 |
Restasis® | Nanoemulsion | Cyclosporine A | Dry eye disease | 2002 |
Retisert® | Implant | Fluclorolone | Uveitis and macular edema | 2005 |
Triesence® | Nanoparticles | Triamcinolone acetonide | Dry eye disease | 2007 |
AzaSite® | Micelles | Azithromycin | DED; keratitis; eye inflammation | 2007 |
Durezol® | Nanoemulsion | Difluprednate | Eye infection and pain | 2008 |
Cationorm® | Nanoemulsion | Medical device | Dry eye disease | 2008 |
Trivarisâ„¢ | Nanoparticles | Triamcinolone acetonide | Uveitis | 2008 |
Besivance® | Nanosuspension | Besifloxacin | Ocular bacterial infection | 2009 |
Tobradex ST® | Nanosuspension | Tobramycin Dexamethasone | Ocular inflammation and bacterial infection | 2009 |
Ikervis® | Nanoemulsion | Cyclosporine A | Keratitis | 2015 |
BromSite® | Solution | Bromfenac | Postoperative inflammation and pain | 2016 |
Cequa® | Micelle | Cyclosporine A | Dry eye disease | 2018 |
Inveltys® | Nanosuspension | Loteprednol etabonate | Postoperative ocular inflammation and pain | 2018 |
Xelpros® | Nanoemulsion | Latanopros | Open-angle glaucoma or high intraocular pressure | 2018 |
Eysuvis® | Nanosuspension | Loteprednol etabonate | Dry eye disesae | 2020 |
Verkazia® | Nanoemulsion | Cyclosporine | Vernal keratoconjunctivitis | 2021 |
Cyclokat® | Nanoemulsion | Cyclosporine A | Dry eye disease | NA |
Lacrisek® | Liposomal spray | Vitamin A, E | Dry eye disease | NA |
Artelac Rebalance® | Liposomal eye drops | Vitamin B12 | Dry eye disease | NA |